1. Home
  2. VRAR vs NCNA Comparison

VRAR vs NCNA Comparison

Compare VRAR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Glimpse Group Inc.

VRAR

The Glimpse Group Inc.

HOLD

Current Price

$1.19

Market Cap

17.2M

Sector

Technology

ML Signal

HOLD

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$3.25

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAR
NCNA
Founded
2016
1997
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
13.8M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
VRAR
NCNA
Price
$1.19
$3.25
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.62
N/A
AVG Volume (30 Days)
172.5K
83.3K
Earning Date
02-12-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,488,209.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$72.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.60
N/A
52 Week Low
$0.77
$2.78
52 Week High
$2.05
$268.00

Technical Indicators

Market Signals
Indicator
VRAR
NCNA
Relative Strength Index (RSI) 59.98 41.26
Support Level $1.03 $3.14
Resistance Level $1.17 $3.35
Average True Range (ATR) 0.11 0.20
MACD 0.02 -0.01
Stochastic Oscillator 81.08 17.91

Price Performance

Historical Comparison
VRAR
NCNA

About VRAR The Glimpse Group Inc.

The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Share on Social Networks: